INT76229

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.33
First Reported 1998
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 5
Total Number 5
Disease Relevance 1.46
Pain Relevance 3.66

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endoplasmic reticulum (BDKRB1) plasma membrane (BDKRB1) signal transducer activity (BDKRB1)
Anatomy Link Frequency
skin 1
BDKRB1 (Homo sapiens)
Pain Link Frequency Relevance Heat
bradykinin 52 100.00 Very High Very High Very High
Pain 11 100.00 Very High Very High Very High
B1 receptor 8 100.00 Very High Very High Very High
antagonist 11 99.96 Very High Very High Very High
agonist 10 99.96 Very High Very High Very High
b2 receptor 8 99.84 Very High Very High Very High
Bioavailability 2 99.60 Very High Very High Very High
Inflammation 6 97.56 Very High Very High Very High
Lasting pain 1 96.88 Very High Very High Very High
nociceptor 1 95.84 Very High Very High Very High
Disease Link Frequency Relevance Heat
Pain 10 96.88 Very High Very High Very High
INFLAMMATION 7 94.60 High High
Nociception 1 91.28 High High
Tics 1 74.44 Quite High
Hereditary Angioedema 35 68.52 Quite High
Pressure And Volume Under Development 18 63.72 Quite High
Increased Venous Pressure Under Development 5 63.32 Quite High
Erythema 2 60.32 Quite High
Systemic Lupus Erythematosus 1 52.44 Quite High
Obesity 1 28.80 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Sensitization to bradykinin B1 and B2 receptor activation in UV-B irradiated human skin.
bradykinin B1 Binding (Sensitization) of in skin associated with pain, b2 receptor and bradykinin
1) Confidence 0.33 Published 2004 Journal Pain Section Title Doc Link 15275768 Disease Relevance 0.63 Pain Relevance 1.00
Novel antagonists were designed that display low-nanomolar affinity for the human bradykinin B1 receptor and good bioavailability in the rat.
bradykinin B1 receptor Binding (affinity) of associated with b1 receptor, antagonist and bioavailability
2) Confidence 0.32 Published 2006 Journal J. Med. Chem. Section Abstract Doc Link 16480259 Disease Relevance 0.10 Pain Relevance 0.42
Competition for [3H]DALKD binding with BK receptor agonists was in the order: [des-Arg10]KD (DAKD) > KD >> [des-Arg9]BK (DABK) > BK, and competition for [3H]DALKD binding with BK receptor antagonists was in the order: DALKD > [des-Arg10]Hoe 140 (DAHoe 140) > [des-Arg9,Leu8]BK (DALBK) > NPC17731 > Hoe 140 > DNMFBK, suggesting that [3H]DALKD bound selectively to B1 receptors.
BK receptor Binding (binding) of associated with antagonist, agonist and bradykinin
3) Confidence 0.24 Published 1998 Journal Life Sci. Section Abstract Doc Link 9651119 Disease Relevance 0.12 Pain Relevance 0.93
Competition for [3H]DALKD binding with BK receptor agonists was in the order: [des-Arg10]KD (DAKD) > KD >> [des-Arg9]BK (DABK) > BK, and competition for [3H]DALKD binding with BK receptor antagonists was in the order: DALKD > [des-Arg10]Hoe 140 (DAHoe 140) > [des-Arg9,Leu8]BK (DALBK) > NPC17731 > Hoe 140 > DNMFBK, suggesting that [3H]DALKD bound selectively to B1 receptors.
BK receptor Binding (binding) of associated with antagonist, agonist and bradykinin
4) Confidence 0.24 Published 1998 Journal Life Sci. Section Abstract Doc Link 9651119 Disease Relevance 0.13 Pain Relevance 0.93
Icatibant is a specific competitive antagonist with similar affinity to bradykinin (1–10 nM) for the B2 receptor, while affinity for the B1 receptor is 100-fold lower.
B1 receptor Binding (affinity) of associated with b1 receptor, antagonist, b2 receptor and bradykinin
5) Confidence 0.03 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941790 Disease Relevance 0.49 Pain Relevance 0.39

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox